Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azathioprine sodium
Drug ID BADD_D00196
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D03033
MeSH ID D001379
PubChem ID 11529527
TTD Drug ID D07QCE
NDC Product Code 0143-9566
UNII AM94R510MS
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H6N7NaO2S
CAS Registry Number 55774-33-9
SMILES CN1C=NC(=C1SC2=NC=NC3=C2N=C[N-]3)[N+](=O)[O-].[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Acute febrile neutrophilic dermatosis01.02.01.006; 23.03.03.033---
Alopecia23.02.02.001--
Anaemia macrocytic01.03.02.002; 14.12.01.002---
Arthralgia15.01.02.001--
Blood bilirubin13.03.04.015---
Diarrhoea07.02.01.001--
Hepatotoxicity09.01.07.009; 12.03.01.008---
Infection11.01.08.002---
Interstitial lung disease10.02.01.033; 22.01.02.003---
Leukopenia01.02.02.001---
Lymphoma01.12.01.001; 16.20.01.001---
Malaise08.01.01.003--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Neoplasm16.16.02.001---
Nitrogen balance negative13.13.01.010---
Pyrexia08.05.02.003--
Rash23.03.13.001---
Rheumatoid arthritis10.04.06.001; 15.01.03.001---
Steatorrhoea07.17.01.002---
Vomiting07.01.07.003--
Transaminases13.03.04.033---
Haemorrhage24.07.01.002---
Blood alkaline phosphatase increased13.04.02.004--
Bone marrow failure01.03.03.005--
Hepatosplenic T-cell lymphoma01.11.01.001; 16.17.01.001---
The 1th Page    1    Total 1 Pages